Endicott Alyson A, Morimoto Libby M, Kline Cassie N, Wiemels Joseph L, Metayer Catherine, Walsh Kyle M
Division of Neuroepidemiology, Department of Neurological Surgery, University of California, San Francisco, California.
Program in Pediatric Malignancies, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California.
Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26349. Epub 2016 Nov 10.
Osteosarcoma typically develops during puberty with tumors arising at sites of rapid bone growth, suggesting a role for growth-regulating pathways in tumor etiology. Birthweight is one measure of perinatal growth that has been investigated as an osteosarcoma risk factor. Whether birthweight affects clinical features of osteosarcoma remains unexplored.
Six hundred seventy patients with osteosarcoma, aged 0-19 years, were identified through the California Cancer Registry. We analyzed birth certificate data from the California Department of Public Health vital statistics unit for these patients and 2,860 controls, matched by sex, birth-year, and race/ethnicity. We examined the impact of birthweight on the risk, timing, and clinical presentation of pediatric osteosarcoma including tumor location, size, extension, differentiation, presence of metastasis, and age at onset. Regression models were adjusted for race, sex, gestational age, socioeconomic status, and tumor site.
Higher birthweight was associated with more advanced tumor stage (P = 0.017), a trend toward greater tumor extension into surrounding tissues (P = 0.083), and with occurrence of tumors in sites other than the long bones of the arms/legs (P = 9.7 × 10 ). Higher birthweight was also associated with an increased likelihood of metastases present at diagnosis (P = 0.047), with each 200 g increase in birthweight associated with a 1.11-fold increase in the odds of having metastatic disease (95% confidence interval: 1.01-1.22).
The association between higher birthweight and more aggressive osteosarcoma, frequently occurring at sites other than the long bones, suggests that growth pathways active during gestation may play an important role in future osteosarcoma progression, especially at anatomic sites with diminished rates of osteoblastic proliferation.
骨肉瘤通常在青春期发病,肿瘤多发生于骨快速生长的部位,提示生长调节通路在肿瘤病因学中起作用。出生体重是围产期生长的一种衡量指标,已被作为骨肉瘤的一个危险因素进行研究。出生体重是否影响骨肉瘤的临床特征仍未明确。
通过加利福尼亚癌症登记处确定了670例年龄在0至19岁之间的骨肉瘤患者。我们分析了加利福尼亚州公共卫生部生命统计部门提供的这些患者以及2860名对照者的出生证明数据,对照者按性别、出生年份和种族/民族进行匹配。我们研究了出生体重对小儿骨肉瘤的风险、发病时间和临床表现的影响,包括肿瘤位置、大小、侵犯范围、分化程度、转移情况以及发病年龄。回归模型对种族、性别、孕周、社会经济地位和肿瘤部位进行了校正。
出生体重较高与肿瘤分期更晚相关(P = 0.017),肿瘤向周围组织侵犯更严重的趋势(P = 0.083),以及肿瘤发生于手臂/腿部长骨以外部位相关(P = 9.7×10⁻⁴)。出生体重较高还与诊断时出现转移的可能性增加相关(P = 0.047),出生体重每增加200克,发生转移性疾病的几率增加1.11倍(95%置信区间:1.01 - 1.22)。
出生体重较高与更具侵袭性的骨肉瘤相关,且骨肉瘤常发生于长骨以外的部位,这表明孕期活跃的生长通路可能在未来骨肉瘤进展中起重要作用,尤其是在成骨细胞增殖率降低的解剖部位。